Targeting the complement system in pancreatic cancer drug resistance: a novel therapeutic approach

Abstract

Pancreatic cancer is ranked as the fourth leading cause of cancer-related mortality and is predicted to become the second leading cause of cancer-related death by 2030. The cause of this high mortality rate is due to pancreatic ductal adenocarcinoma’s rapid progression and metastasis, and development of drug resistance. Today, cancer immunotherapy is becoming a strong candidate to not only treat various cancers but also to combat against chemoresistance. Studies have suggested that complement system pathways play an important role in cancer progression and chemoresistance, especially in pancreatic cancer. A recent report also suggested that several signaling pathways play an important role in causing chemoresistance in pancreatic cancer, major ones including nuclear factor kappa B, signal transducer and activator of transcription 3, c-mesenchymal-epithelial transition factor, and phosphoinositide-3-kinase/protein kinase B. In addition, it has also been proven that the complement system has a very active role in establishing the tumor microenvironment, which would aid in promoting tumorigenesis, progression, metastasis, and recurrence. Interestingly, it has been shown that the downstream products of the complement system directly upregulate inflammatory mediators, which in turn activate these chemo-resistant pathways. Therefore, targeting complement pathways could be an innovative approach to combat against pancreatic cancer drugs resistance. In this review, we have discussed the role of complement system pathways in pancreatic cancer drug resistance and a special focus on the complement as a therapeutic target in pancreatic cancer.

Keywords

Pancreatic cancer / complement system / immunotherapy / drug resistance / nuclear factor kappa B (NF-κB) / signal transducer and activator of transcription (STAT3) / c-mesenchymal-epithelial transition factor (C-MET) / phosphoinositide-3-kinase/protein kinase B (PI3K/AKT)

References

[1] Zeng S,Lan B,Pilarsky C.Chemoresistance in pancreatic cancer.Int J Mol Sci2019;20:4504 PMCID:PMC6770382

[2] Riker A,Bartlett DL.Advances in the early detection, diagnosis, and staging of pancreatic cancer.Surgical Oncology1997;6:157-69

[3] Swayden M,Soubeyran P.Pancreatic cancer chemo-resistance is driven by tumor phenotype rather than tumor genotype.Heliyon2018;4:e01055 PMCID:PMC6299038

[4] Li Q,Feng M.NF-κB in pancreatic cancer: its key role in chemoresistance.Cancer Lett2018;421:127-34

[5] Coussens LM.Inflammation and cancer.Nature2002;420:860-7 PMCID:PMC2803035

[6] Dudley DJ.1 The immune system in health and disease.Baillière's Clinical Obstetrics and Gynaecology1992;6:393-416

[7] Netti GS,Stasi A.Role of complement in regulating inflammation processes in renal and prostate cancers.Cells2021;10:2426 PMCID:PMC8471315

[8] Zhang R,Li T,Zhao Y.Role of the complement system in the tumor microenvironment.Cancer Cell Int2019;19:300 PMCID:PMC6858723

[9] Merle NS,Fremeaux-Bacchi V.Complement system part i - molecular mechanisms of activation and regulation.Front Immunol2015;6:262 PMCID:PMC4451739

[10] Merle NS,Halbwachs-Mecarelli L,Roumenina LT.Complement system part II: role in immunity.Front Immunol2015;6:257 PMCID:PMC4443744

[11] Hanahan D.Hallmarks of cancer: the next generation.Cell2011;144:646-74

[12] Afshar-Kharghan V.The role of the complement system in cancer.J Clin Invest2017;127:780-9 PMCID:PMC5330758

[13] Ajona D,Pio R.Complement anaphylatoxins C3a and C5a: emerging roles in cancer progression and treatment.Semin Cell Dev Biol2019;85:153-63

[14] Zhu H,Zhang S.Targeting the complement pathway in malignant glioma microenvironments.Front Cell Dev Biol2021;9:657472 PMCID:PMC8047198

[15] Bonavita E,Rubino M.PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer.Cell2015;160:700-14

[16] Pio R,Lambris JD.Complement inhibition in cancer therapy.Semin Immunol2013;25:54-64 PMCID:PMC3733085

[17] Quiñonero F,Doello K.The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview.Cancer Biol Med2019;16:688-99 PMCID:PMC6936232

[18] Zheng HC.The molecular mechanisms of chemoresistance in cancers.Oncotarget2017;8:59950-64 PMCID:PMC5601792

[19] Randazzo O,Mantini G.“Open Sesame?.Cancers (Basel)2020;12:3206 PMCID:PMC7692081

[20] Bergman AM,Peters GJ.Determinants of resistance to 2’,2’-difluorodeoxycytidine (gemcitabine).Drug Resistance Updates2002;5:19-33

[21] Kim J,Lee JC.Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer.PLoS One2018;13:e0209104 PMCID:PMC6296552

[22] Ferreira CG,Peters GJ,Giaccone G.Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res 2000;60:7133-41. Available from: https://aacrjournals.org/cancerres/article/60/24/7133/507101/Chemotherapy-Triggers-Apoptosis-in-a-Caspase-8 [Last accessed on 28 Mar 2022]

[23] Pramanik KC,Bhowmick K.Advancement of NF-κB signaling pathway: a novel target in pancreatic cancer.Int J Mol Sci2018;19:3890 PMCID:PMC6320793

[24] Wang W,Evans DB.Clin Cancer Res1999;5:119-27

[25] Liptay S,Ludwig L,Adler G.Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer.Int J Cancer2003;105:735-46

[26] Bettac L,Seufferlein T.Complement in pancreatic disease-perpetrator or savior?.Front Immunol2017;8:15 PMCID:PMC5239781

[27] Xia L,Zhou Y.Role of the NFκB-signaling pathway in cancer.Onco Targets Ther2018;11:2063-73 PMCID:PMC5905465

[28] Lu N.Extracellular signal-regulated kinase: a regulator of cell growth, inflammation, chondrocyte and bone cell receptor-mediated gene expression.Int J Mol Sci2019;20:3792 PMCID:PMC6696446

[29] Salaroglio IC,Gazzano E,Riganti C.ERK is a pivotal player of chemo-immune-resistance in cancer.Int J Mol Sci2019;20:2505 PMCID:PMC6566596

[30] Hung SW,Cummins S.Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach.Cancer Lett2015;359:233-40 PMCID:PMC4433543

[31] Bentires-Alj M,Fillet M.NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells.Oncogene2003;22:90-7

[32] Organ SL.An overview of the c-MET signaling pathway.Ther Adv Med Oncol2011;3:S7-S19 PMCID:PMC3225017

[33] Ilic M.Epidemiology of pancreatic cancer.World J Gastroenterol2016;22:9694-705 PMCID:PMC5124974

[34] Noguchi K,Eguchi H.c-Met affects gemcitabine resistance during carcinogenesis in a mouse model of pancreatic cancer.Oncol Lett2018;16:1892-8 PMCID:PMC6036484

[35] Delitto D,Hughes SJ,Trevino JG.c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer.World J Gastroenterol2014;20:8458-70 PMCID:PMC4093697

[36] Chen H,Yang LF.Targeting STAT3 by a small molecule suppresses pancreatic cancer progression.Oncogene2021;40:1440-57 PMCID:PMC7906907

[37] Rébé C,Berger H.STAT3 activation: a key factor in tumor immunoescape.JAKSTAT2013;2:e23010 PMCID:PMC3670267

[38] Yuan K,Liu Z.Complement C3 overexpression activates JAK2/STAT3 pathway and correlates with gastric cancer progression.J Exp Clin Cancer Res2020;39:9 PMCID:PMC6956509

[39] Liu XY,Shi Y. Recent advances in cancer research and therapy. 1st ed. London: Elsevier Science; 2012. Available from: https://books.google.com.hk/books?hl=zh-CN&lr=&id=RaorzeM2kuYC&oi=fnd&pg=PP1&dq=Recent+advances+in+cancer+research+and+therapy&ots=PU8uf32xC6&sig=FQ7nAFZyCSqh67TGXU0QBca2QFk&redir_esc=y#v=onepage&q=Recent%20advances%20in%20cancer%20research%20and%20therapy&f=false [Last accessed on 28 Mar 2022]

[40] Valle-Mendiola A.Energy metabolism in cancer: the roles of STAT3 and STAT5 in the regulation of metabolism-related genes.Cancers (Basel)2020;12:124 PMCID:PMC7016889

[41] Shih PC.Role of STAT3 signaling transduction pathways in cancer stem cell-associated chemoresistance.Drug Discov Today2021;26:1450-8

[42] Liu R,Liu G.PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers.Cell Death Dis2020;11:797 PMCID:PMC7515865

[43] Zhang Y,Collins MA.Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance.Cancer Res2013;73:6359-74 PMCID:PMC3831882

[44] Baer R,Therville N.Implication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter?.Adv Biol Regul2015;59:19-35

[45] Kleczko EK,Schenk EL.Targeting the complement pathway as a therapeutic strategy in lung cancer.Front Immunol2019;10:954 PMCID:PMC6522855